Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sars-CoV2 Clear all
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

NCT04415073
View directory record Official record
Conditions
Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions
SNDX-6352, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Scottsdale, Arizona • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 1 Interventional Results available

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

NCT04397796
View directory record Official record
Conditions
COVID
Interventions
BM-Allo.MSC, Placebo
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-AUTONOMIC Platform Protocol

NCT06305780
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Not applicable Interventional

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

NCT04397692
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS-CoV 2, Nitric Oxide, Respiratory Disease, Pneumonia, Viral, Inhaled Nitric Oxide
Interventions
Nitric Oxide delivered via LungFit™ system
Device
Lead sponsor
Beyond Air Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

NCT05210101
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
Sotrovimab
Drug
Lead sponsor
Sophia Koo, M.D.
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Completed No phase listed Observational

WGS Analysis of COVID-19 Positive Patients

NCT04353401
View directory record Official record
Conditions
Coronavirus Infection, COVID-19
Interventions
Not listed
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated No phase listed Observational

Serology to COVID-19 for Recording Exposures and Evaluating Needs

NCT04566965
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
232 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

NCT04583228
View directory record Official record
Conditions
COVID 19
Interventions
HLX71, Placebo
Drug · Other
Lead sponsor
Hengenix Biotech Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Qigong for Post Acute Sequelae of COVID-19 Infection

NCT05675995
View directory record Official record
Conditions
Long COVID
Interventions
Qigong
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed No phase listed Observational

Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)

NCT04339998
View directory record Official record
Conditions
Coronavirus Infection, COVID, Covid-19, SARS-CoV-2
Interventions
Point-of-Care Ultrasonography (POCUS)
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen

NCT04805840
View directory record Official record
Conditions
Covid19
Interventions
CoV-SCAN rapid COVID-19 antigen test
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-235 in Healthy Subjects

NCT05246878
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

NCT06633835
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
Interventions
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Withdrawn Phase 3 Interventional

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552
View directory record Official record
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

NCT04955626
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
16,372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
139
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

NCT04365153
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study

NCT04964154
View directory record Official record
Conditions
Covid19 Virus Infection
Interventions
Protect Your Elders Campaign
Behavioral
Lead sponsor
North Carolina Central University
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pembroke, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

NCT05541861
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg, BNT162b4 15 mcg, BNT162b4 30 mcg, BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Tempe, Arizona • Newport Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional Results available

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

NCT04409873
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
Interventions
Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 26, 2026, 4:34 AM EDT